Evaluation of the Effectiveness of Additional Risk Minimization Measures for Ixazomib Citrate for Relapsed/Refractory Multiple Myeloma in Japan: A Web-Based Survey Among Pharmacists
How to take IXA was explained to patients by pharmacists and the aRMM material was utilized at the time of the explanation, indicating that the aRMM material contributes to the promotion of the appropriate use of IXA.
Authors
- Seigo Seki (ORCID: https://orcid.org/0009-0001-1501-9981)
- Motonobu Sakaguchi (ORCID: https://orcid.org/0000-0003-2310-6812)
- Yoshiko Maeda (ORCID: https://orcid.org/0009-0006-6115-2755)
- Y. KATSURA (ORCID: https://orcid.org/0009-0000-7738-1970)
- Akihito Abe (ORCID: https://orcid.org/0009-0005-8799-5438)
- Y Muramatsu (ORCID: https://orcid.org/0009-0006-2394-3556)
- Nobuhiro Narii (ORCID: https://orcid.org/0000-0002-0826-1358)
Institutions
- Takeda (Japan) (JP)
Publication Details
- Journal
- Pharmaceutical Medicine
- Published
- 2024-08-21
- DOI
- https://doi.org/10.1007/s40290-024-00535-w
- Primary Topic
- Multiple Myeloma Research and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Takeda Pharmaceutical Company